Sanofi · 19 hours ago
Principal Scientist, Retinal Degeneration
Cambridge, MA
Full-time
Onsite
Senior Level, Lead/Staff
5+ years expSanofi is a biopharmaceutical company dedicated to improving lives through innovative research. The Principal Scientist will lead preclinical drug discovery programs for retinal diseases, utilizing advanced experimental approaches to validate therapeutic strategies and collaborate with cross-functional teams.
Health CareLife SciencePharmaceuticalTherapeutics
Responsibilities
Apply scientific expertise and judgement to initiate, design, direct, and execute research studies to translate new targets from discovery to therapeutic disease programs and preclinical development
Work independently, proactively and be an impactful contributor and leader of research projects and pipeline programs in a matrixed team environment to achieve go/no-go decisions
Design, conduct, and direct in vitro mechanism-of-action, proof-of-concept, and biomarker studies to validate targets and evaluate neuroprotective therapeutic strategies
Collaborate cross-functionally to screen preclinical candidates of diverse modalities using target- and disease-relevant functional readouts that inform on pharmacology and efficacy
Actively contribute to interdisciplinary research programs in a highly collaborative manner across internal groups and with external partners
Prepare high-quality analyses, interpretation, documentation, and presentations to support project milestones, publications, patent filings, and regulatory (IND/CTA) filings
Present project data packages at governance meetings
Grow a reputation in the internal and external scientific community through high impact publications, productive scientific collaborations and active participation in conferences
Qualification
Required
Earned Ph.D. or equivalent degree in cell biology, neuroscience, or other relevant scientific discipline, and 5+ years of research experience in biopharmaceutical or academic setting
Demonstrated experience (1 year or more ideally) in drug development at a biopharmaceutical company
Experience evaluating and validating new therapeutic targets required, preferably for retinal or neurodegenerative diseases
Extensive cell culture experience, including work with primary cells, iPSC-derived cells, or 3D in vitro models
Comprehensive experience with a broad range of molecular, cellular, and biochemical methods, assay development, and in vitro disease modeling
Experience preparing high-quality documents including experimental protocols, SOPs, technical reports, and presentations
Track record of significant contributions to research projects and scientific publications
Preferred
Experience in retinal disease and degeneration or neurodegeneration research strongly preferred
Experience using computational approaches (e.g., R, Python) to analyze data strongly preferred
Program leadership experience in an industry setting
Experience authoring regulatory documents to support IND or CTA applications with agencies like the FDA and EMA
Experience managing studies at CROs
Familiarity with wide range of therapeutic modalities including biologics, small molecules, and/or genomic medicines
Experience in high-throughput assay development and using automated screening platforms and robotics
Experience with animal models of retinal disease and degeneration
Benefits
High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave
Company
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.
10001+ employees
H1B Sponsorship
Sanofi has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (101)
2024 (68)
2023 (59)
2022 (78)
2021 (38)
2020 (38)
Funding
Current Stage
Public CompanyTotal Funding
$6.97BKey Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B
Leadership Team
Paul Hudson
Chief Executive Officer
Francois-Xavier Roger
Chief Financial Officer
Recent News
2026-01-08
2026-01-08
Company data provided by crunchbase